Harvard Bioscience (HBIO) Competitors

OptimizeRx (NASDAQ:OPRX) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Do analysts rate OPRX or HBIO?

OptimizeRx currently has a consensus target price of $15.86, indicating a potential upside of 52.18%. Given Harvard Bioscience's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OptimizeRx	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
Harvard Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has more risk & volatility, OPRX or HBIO?

OptimizeRx has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Do insiders & institutionals have more ownership in OPRX or HBIO?

76.5% of OptimizeRx shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 4.4% of OptimizeRx shares are held by company insiders. Comparatively, 9.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Is OPRX or HBIO more profitable?

Harvard Bioscience has a net margin of -3.04% compared to Harvard Bioscience's net margin of -24.56%. OptimizeRx's return on equity of 2.75% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OptimizeRx	-24.56%	-7.72%	-6.65%
Harvard Bioscience	-3.04%	2.75%	1.45%

Does the media prefer OPRX or HBIO?

In the previous week, Harvard Bioscience had 32 more articles in the media than OptimizeRx. MarketBeat recorded 37 mentions for Harvard Bioscience and 5 mentions for OptimizeRx. Harvard Bioscience's average media sentiment score of 0.48 beat OptimizeRx's score of -0.21 indicating that OptimizeRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OptimizeRx	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Harvard Bioscience	2 Very Positive mention(s)	1 Positive mention(s)	14 Neutral mention(s)	16 Negative mention(s)	3 Very Negative mention(s)	Neutral

Which has better earnings & valuation, OPRX or HBIO?

Harvard Bioscience has higher revenue and earnings than OptimizeRx. Harvard Bioscience is trading at a lower price-to-earnings ratio than OptimizeRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OptimizeRx	$71.52M	2.65	-$17.57M	-$1.01	-10.32
Harvard Bioscience	$112.25M	1.48	-$3.41M	-$0.08	-47.74

Does the MarketBeat Community favor OPRX or HBIO?

Harvard Bioscience received 226 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 72.16% of users gave Harvard Bioscience an outperform vote while only 62.83% of users gave OptimizeRx an outperform vote.

Company	Underperform	Outperform
OptimizeRx	Outperform Votes 142 62.83%	Underperform Votes 84 37.17%
Harvard Bioscience	Outperform Votes 368 72.16%	Underperform Votes 142 27.84%

Summary

Harvard Bioscience beats OptimizeRx on 12 of the 17 factors compared between the two stocks.